FDA Requires New GLP-1 Drug Warnings About a Potential Risk of Rare but Permanent Vision Loss

GLP-1 RAs and five in patients receiving placebo. None were detected in participants who were taking other glucose-lowering medications. When expressed as incidence rates, this translated to 6.4 NAION cases per 100,000 person-years among GLP-1 RA users and 3.8 per 100,000 person-years among those on comparators.

The small number of cases means that the absolute risk remains low and the estimates are imprecise, which the FDA openly acknowledges. The agency also reviewed animal data and did not identify a clear biological mechanism to explain how GLP-1

Leave a Reply

Your email address will not be published. Required fields are marked *